All children have been enrolled in a phase IIb study in The Gambia evaluating the efficacy of a highly promising vaccine against enterotoxigenic E. coli., known as ETVAX®. The ETEC ETVAX project is developing a new formulation of ETVAX® that will be better suited to young children, as well as a convenient device for administering the vaccine.
The ETEC Vaccine Efficacy consortium conducts the phase IIb clinical trial to generate evidence to support WHO prequalification of the vaccine. The project will also strengthen clinical trial and laboratory capabilities in both The Gambia and Zambia, particularly expertise in new microbiological and immunological techniques.